Psoriasis: It's more than just the skin

Journal of Lipid Research

Volumn 53, Issue 8, 2012, Pages 1427-1429

  Feingold, Kenneth R ^a   Grunfeld, Carl ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; RETINOID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF LIPOPROTEIN METABOLISM; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID COMPOSITION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION; PSORIASIS; RHEUMATOID ARTHRITIS; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

CHOLESTEROL; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; PSORIASIS;

EID: 84863788707     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E029330     Document Type: Note

References (21)

1. Nestle, F. O., D. H. Kaplan, and J. Barker. 2009. Psoriasis. N. Engl. J. Med. 361: 496-509.
2. Friedewald, V. E., J. C. Cather, J. M. Gelfand, K. B. Gordon, G. H. Gibbons, S. M. Grundy, M. T. Jarratt, J. G. Krueger, P. M. Ridker, N. Stone, et al. 2008. AJC editor's consensus: psoriasis and coronary artery disease. Am. J. Cardiol. 102: 1631-1643.
3. Gottlieb, A. B., and F. Dann. 2009. Comorbidities in patients with psoriasis. Am. J. Med. 122: 1150. e1-9.
4. Tobin, A. M., D. J. Veale, O. Fitzgerald, S. Rogers, P. Collins, D. O'Shea, and B. Kirby. 2010. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J. Rheumatol. 37: 1386-1394.
5. McDonald, C. J., and P. Calabresi. 1978. Psoriasis and occlusive vascular disease. Br. J. Dermatol. 99: 469-475. (Pubitemid 9048948)
6. Balci, D. D., A. Balci, S. Karazincir, E. Ucar, U. Iyigun, F. Yalcin, E. Seyfeli, T. Inandi, and E. Egilmez. 2009. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J. Eur. Acad. Dermatol. Venereol. 23: 1-6.
7. El-Mongy, S., H. Fathy, A. Abdelaziz, E. Omran, S. George, N. Neseem, and N. El-Nour. 2010. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J. Eur. Acad. Dermatol. Venereol. 24: 661-666.
8. Ludwig, R. J., C. Herzog, A. Rostock, F. R. Ochsendorf, T. M. Zollner, D. Thaci, R. Kaufmann, T. J. Vogl, and W. H. Boehncke. 2007. Psoriasis: a possible risk factor for development of coronary artery calcification. Br. J. Dermatol. 156: 271-276. (Pubitemid 46095954)
9. van Leuven, S. I., R. Franssen, J. J. Kastelein, M. Levi, E. S. Stroes, and P. P. Tak. 2008. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford). 47: 3-7. (Pubitemid 350286254)
10. Khovidhunkit, W., M. S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196. (Pubitemid 38802622)
11. Hotamisligil, G. S. 2006. Inflammation and metabolic disorders. Nature. 444: 860-867. (Pubitemid 46024993)
12. Holzer, M., P. Wolf, S. Curcic, R. Birner-Gruenberger, W. Weger, M. Inzinger, D. El-Gamal, C. Wadsack, A. Heinemann, and G. Marsche. Psoriasis alters HDL composition and cholesterol efflux capacity. J. Lipid Res. 53: 1618-1624.
13. Rosenson, R. S., H. B. Brewer, Jr., W. S. Davidson, Z. A. Fayad, V. Fuster, J. Goldstein, M. Hellerstein, X. C. Jiang, M. C. Phillips, D. J. Rader, et al. 2012. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 125: 1905-1919.
14. Feingold, K. R., and C. Grunfeld. 2010. The acute phase response inhibits reverse cholesterol transport. J. Lipid Res. 51: 682-684.
15. Khovidhunkit, W., J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2001. Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin: cholesterol acyltransferase. J. Lipid Res. 42: 967-975. (Pubitemid 32545853)
16. de la Llera Moya, M., F. C. McGillicuddy, C. C. Hinkle, M. Byrne, M. R. Joshi, V. Nguyen, J. Tabita-Martinez, M. L. Wolfe, K. Badellino, L. Pruscino, et al. 2012. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis. 222: 390-394.
17. Charles-Schoeman, C., Y. Y. Lee, V. Grijalva, S. Amjadi, J. Fitzgerald, V. K. Ranganath, M. Taylor, M. McMahon, H. E. Paulus, and S. T. Reddy. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann. Rheum. Dis. Epub ahead of print. January 20, 2012.
18. Navab, M., S. T. Reddy, B. J. Van Lenten, G. M. Anantharamaiah, and A. M. Fogelman. 2009. The role of dysfunctional HDL in atherosclerosis. J. Lipid Res. 50 (Suppl) : S145-S149.
19. Charles-Schoeman, C., J. Watanabe, Y. Y. Lee, D. E. Furst, S. Amjadi, D. Elashoff, G. Park, M. McMahon, H. E. Paulus, and A. M. Fogelman, et al. 2009. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 60: 2870-2879.
20. Kelesidis, T., O. O. Yang, J. S. Currier, K. Navab, A. M. Fogelman, and M. Navab. 2011. HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids Health Dis. 10: 35.
21. McMahon, M., J. Grossman, J. FitzGerald, E. Dahlin-Lee, D. J. Wallace, B. Y. Thong, H. Badsha, K. Kalunian, C. Charles, and M. Navab, et al. 2006. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54: 2541-2549. (Pubitemid 44205015)